Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis” Kristian Reich, Craig Leonardi,

Slides:

Advertisements

Similar presentations

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Advertisements

All-Cause and Cause-Specific Mortality in Patients with Psoriasis in Taiwan: A Nationwide Population-Based Study Meng-Sui Lee, Yi-Chun Yeh, Yun-Ting.

Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study Ingrid Snekvik, Catherine H. Smith,

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis Zenas Z.N. Yiu, Lesley S. Exton, Zarif.

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu,

Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Expanding Our Understanding of Human Skin Aging

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Skin-Derived Vitamin D3 Protects against Basal Cell Carcinoma

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A Score with a VESted Interest in Vitiligo

Michael L. Frisoli, John E. Harris

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study Robert Bissonnette, François Harel,

Research Techniques Made Simple: Workflow for Searching Databases to Reduce Evidence Selection Bias in Systematic Reviews Laurence Le Cleach, Elizabeth.

Clinical Snippets Journal of Investigative Dermatology

Rosa Parisi, Deborah P. M. Symmons, Christopher E. M

Aaron M. Drucker, Patrick Fleming, An-Wen Chan

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N.

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

PXR: A New Player in Atopic Dermatitis

Luigi Naldi Journal of Investigative Dermatology

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis Alexander Nast, Anja Jacobs,

Joanne E. Sordillo, Peter Kraft, Ann Chen Wu, Maryam M. Asgari

Research Techniques Made Simple: Network Meta-Analysis

Risk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study Alexander Egeberg, Lotus Mallbris, Gunnar Hilmar Gislason, Lone.

Clinical Snippets Journal of Investigative Dermatology

Research Techniques Made Simple: Cost-Effectiveness Analysis

Treatment of Psoriasis with Interleukin-10

Global Patterns of Methylation in Sézary Syndrome Provide Insight into the Role of Epigenetics in Cutaneous T-Cell Lymphoma Sean Whittaker Journal of.

An Unexpected Role for TRPV4 in Serotonin-Mediated Itch

Influenza Vaccination Rates in Adults with Psoriasis Compared to Adults with Other Chronic Diseases Megan H. Noe, Daniel B. Shin, Rebecca A. Hubbard,

Alexander Egeberg, Gregor B. E. Jemec, Alexa B

Scott A. Elman, James H. Ware, Alice B. Gottlieb, Joseph F. Merola

Tamar Nijsten Journal of Investigative Dermatology

More Than Many: How to Manage the Most Frequent Cancer?

Teledermatology in China: History, Current Status, and the Next Step

Alice Pentland Journal of Investigative Dermatology

Minutes of the Board of Directors Meeting

Journal of Investigative Dermatology

Cancer Stem Cells in Squamous Cell Carcinoma

Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis Chloé Théréné, Emilie Brenaut, Thomas Barnetche,

Clinical Snippets Journal of Investigative Dermatology

Sigrun A.J. Schmidt, Serigne Lo, Loes M. Hollestein

Research Techniques Made Simple: Itch Measurement in Clinical Trials

Journal of Investigative Dermatology

Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology Amy C. Foulkes, David S. Watson, Christopher E.M. Griffiths, Richard B. Warren,

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program Katherine Li, C. Chris Huang, Bruce Randazzo,

Society for Investigative Dermatology 2010 Meeting Minutes

Journal of Investigative Dermatology

Erratum Journal of Investigative Dermatology

Research Snippets Journal of Investigative Dermatology

Reviewer Acknowledgment

BJD Editor’s Choice Journal of Investigative Dermatology

Research Snippets from the British Journal of Dermatology

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Hot on the Trail of Genes that Shape Our Fingerprints

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Journal of Investigative Dermatology

Journal of Investigative Dermatology

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks Esther von Stebut, Kristian.

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis” Kristian Reich, Craig Leonardi, Kim Papp, Alice Gottlieb, Diamant Thaçi, Alexander Schacht, Susan Ball, Noah Agada, Lotus Mallbris Journal of Investigative Dermatology Volume 137, Issue 12, Pages 2642-2644 (December 2017) DOI: 10.1016/j.jid.2017.06.031 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Efficacy compared to tolerability at weeks 12/16. Risk differences from Table 1 of Jabbar-Lopez et al. AE, adverse event; PASI, Psoriasis Area and Severity Index; PGA, Physician's Global Assessment. Journal of Investigative Dermatology 2017 137, 2642-2644DOI: (10.1016/j.jid.2017.06.031) Copyright © 2017 The Authors Terms and Conditions